Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.38% 0.32% 39.51M 6986.33
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
1.15% 31.55% 15.32M Upgrade

Basic Info

Investment Strategy
The ETF seeks to track, to the extent reasonably possible and before the deduction of fees and expenses, the performance of a global equity index which measures the investment return of global issuers related to healthcare. Currently, this TD ETF seeks to track the Solactive Global Healthcare Leaders Index (CA NTR) (or any successor thereto). Solactive Global Healthcare Leaders Index (CA NTR) intends to track the performance of securities of global large and mid-capitalization issuers that are related to healthcare while imposing a limit of 2% to any single issuer. Constituents are subject to minimum market capitalization and liquidity screens.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl GR CAD
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective --
Fund Owner Firm Name TD Asset Management Inc
Prospectus Benchmark Index
Solactive Glb Healthcare Leaders NR CAD 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Not Disclosed 1.82 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 19
15.32M
-112.96M Category Low
467.85M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of January 31, 2023

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of February 03, 2023. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
--
--
--
--
--
--
-1.34%
0.41%
21.36%
9.78%
-7.58%
21.93%
5.56%
28.04%
-6.24%
7.39%
13.27%
20.24%
-13.95%
26.41%
4.64%
20.63%
-8.79%
7.45%
--
--
-10.97%
24.55%
0.97%
15.27%
-0.23%
-1.08%
--
--
--
21.64%
21.23%
10.09%
-24.08%
14.34%
--
--
--
--
--
--
--
--
As of February 03, 2023.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (2-3-23) 1.15%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 22.24
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2022

Asset Allocation

As of December 31, 2022.
Type % Net % Long % Short
Cash 0.54% Upgrade Upgrade
Stock 99.94% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other -0.48% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Gilead Sciences Inc 2.42% 84.50 3.82%
Novo Nordisk A/S Class B
2.36% -- --
Merck & Co Inc 2.31% 102.94 -0.50%
Sanofi SA
2.23% -- --
AstraZeneca PLC
2.22% -- --
Intuitive Surgical Inc 2.18% 254.68 -2.38%
Novartis AG
2.16% -- --
Pfizer Inc 2.14% 44.06 -0.63%
AbbVie Inc 2.08% 145.20 0.25%
Cigna Corp 2.08% 292.59 -2.96%

Basic Info

Investment Strategy
The ETF seeks to track, to the extent reasonably possible and before the deduction of fees and expenses, the performance of a global equity index which measures the investment return of global issuers related to healthcare. Currently, this TD ETF seeks to track the Solactive Global Healthcare Leaders Index (CA NTR) (or any successor thereto). Solactive Global Healthcare Leaders Index (CA NTR) intends to track the performance of securities of global large and mid-capitalization issuers that are related to healthcare while imposing a limit of 2% to any single issuer. Constituents are subject to minimum market capitalization and liquidity screens.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl GR CAD
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective --
Fund Owner Firm Name TD Asset Management Inc
Prospectus Benchmark Index
Solactive Glb Healthcare Leaders NR CAD 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Not Disclosed 1.82 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (2-3-23) 1.15%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 22.24
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2022

Fund Details

Key Dates
Inception Date 4/7/2021
Last Annual Report Date 12/31/2021
Last Prospectus Date 2/24/2022
Attributes
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

Top Portfolio Holders

0 of 0